Swiss pharmaceutical giant Roche on Tuesday announced plans to invest $50 billion in the United States over the next five ...

As a stock-picking sector, investors can benefit from deep fundamental research on individual biotech companies ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

UK leads venture capital investment in Europe in Q1 2025, according to an update from KPMG. The report reveals latest VC ...

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

On the buying side, ARK’s ARKG ETF acquired 2161 shares of biopharmaceutical giant Amgen Inc (NASDAQ: AMGN ), with a total investment of around $599,223. This purchase signals a growing interest in ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

SOLASTA Bio has appointed three senior business and industry experts to support the company’s UK and US growth.

Roche’s drug production operations are set to benefit from the company’s updated U.S. strategy, including with “expanded and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Learn more about whether Alvotech or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a ...